MedPath
FDA Approval

Lamzede

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Chiesi USA, Inc.
DUNS: 088084228
Effective Date
February 21, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Velmanase alfa(10 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Chiesi Farmaceutici S.p.A

439554411

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lamzede

Product Details

NDC Product Code
10122-180
Application Number
BLA761278
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
February 27, 2023
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORMInactive
Code: GR686LBA74Class: IACTQuantity: 2.47 mg in 1 1
GLYCINEInactive
Code: TE7660XO1CClass: IACTQuantity: 10.1 mg in 1 1
MANNITOLInactive
Code: 3OWL53L36AClass: IACTQuantity: 227.5 mg in 1 1
SODIUM PHOSPHATE, MONOBASICInactive
Code: 3980JIH2SWClass: IACTQuantity: 0.088 mg in 1 1
Code: M91TG242P2Class: ACTIBQuantity: 10 mg in 1 1

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

CONTRAINDICATIONS SECTION

Highlight: None. (4)

4****CONTRAINDICATIONS

None.

BOXED WARNING SECTION

WARNING: SEVERE HYPERSENSITIVITY REACTIONS


© Copyright 2025. All Rights Reserved by MedPath